AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 71 filers reported holding AUTOLUS THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $146,000 | -24.0% | 67,517 | 0.0% | 0.00% | – |
| Q2 2022 | $192,000 | +40.1% | 67,517 | +106.4% | 0.00% | – |
| Q1 2022 | $137,000 | -19.4% | 32,704 | 0.0% | 0.00% | – |
| Q4 2021 | $170,000 | -10.5% | 32,704 | +12.8% | 0.00% | – |
| Q3 2021 | $190,000 | +33.8% | 28,984 | +35.8% | 0.00% | – |
| Q2 2021 | $142,000 | +125.4% | 21,337 | +95.9% | 0.00% | – |
| Q1 2021 | $63,000 | -35.1% | 10,891 | 0.0% | 0.00% | – |
| Q4 2020 | $97,000 | -3.0% | 10,891 | +25.8% | 0.00% | – |
| Q3 2020 | $100,000 | -27.5% | 8,660 | 0.0% | 0.00% | – |
| Q2 2020 | $138,000 | +411.1% | 8,660 | +87.3% | 0.00% | – |
| Q1 2020 | $27,000 | -41.3% | 4,623 | +31.5% | 0.00% | – |
| Q4 2019 | $46,000 | +2200.0% | 3,515 | +2307.5% | 0.00% | – |
| Q3 2019 | $2,000 | 0.0% | 146 | 0.0% | 0.00% | – |
| Q2 2019 | $2,000 | +100.0% | 146 | +217.4% | 0.00% | – |
| Q1 2019 | $1,000 | 0.0% | 46 | 0.0% | 0.00% | – |
| Q4 2018 | $1,000 | – | 46 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 21,346,829 | $49,738,112 | 74.10% |
| TFG Asset Management GP Ltd | 12,000,000 | $27,960,000 | 5.10% |
| Paradigm Biocapital Advisors LP | 14,406,782 | $33,567,802 | 2.28% |
| Lynx1 Capital Management LP | 1,363,025 | $3,175,848 | 2.10% |
| Deep Track Capital, LP | 15,000,000 | $34,950,000 | 1.35% |
| Affinity Asset Advisors, LLC | 1,992,466 | $4,642,446 | 1.31% |
| DAFNA Capital Management LLC | 928,253 | $2,162,829 | 0.67% |
| Frazier Life Sciences Management, L.P. | 3,746,857 | $8,730,177 | 0.58% |
| ARMISTICE CAPITAL, LLC | 6,900,000 | $16,077,000 | 0.25% |
| Blackstone Inc. | 20,485,611 | $47,731,474 | 0.20% |